TPO and thyroid cancer: When crossed with p53-flox mice, both TPO-Cre/FR-HrasG12V and TPO-Cre/LSL-KrasG12D models develop PDTCs and ATCs with a latency of 6–10 months, indicating that these transgenic lines provide a robust foundation for creating mouse models of oncogenic Ras-driven advanced thyroid cancers.